Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 27, 2026
An FDA advisory committee spent two days in late July 2026 voting on whether seven peptides should be added to the list of substances that compounding pharmacies are permitted to work with. Six of the seven got a favorable vote — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — while Emideltide (DSIP) was narrowly rejected. Two things make this more complicated than the headlines suggest…
This dispatch covers FDA Advisory Panel Backs 6 of 7 Peptides for Compounding — What the July 23–24 Vote Actually Changes in the General research category, authored by The Peptide Dispatch Editorial Team, originally published in The Peptide Dispatch. Estimated reading time: 5 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
An FDA advisory committee spent two days in late July 2026 voting on whether seven peptides should be added to the list of substances that compounding pharmacies are permitted to work with. Six of the seven got a favorable vote — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — while Emideltide (DSIP) was narrowly rejected. Two things make this more complicated than the headlines suggest. First, the committee voted against the recommendation of FDA's own scientists, whose main objection was that they could not pin down what these substances chemically are well enough to set quality standards. Second, an advisory vote is not a rule change: FDA still has to accept the recommendation and run a full rulemaking process, which typically takes eight months to two years. Nothing about what is legal changed on the day of the vote.
Key takeaways On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven nominated peptides for Category 1 of the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) failed on a 6–7 vote with one abstention. Every vote was split, and every recommendation ran against the written conclusion of the FDA's own scientific review team, which recommended against all seven. The votes are non-binding. No peptide became legal to compound on July 24 that was not legal on July 22. Category 1 placement still requires notice-and-comment rulemaking — a Notice of Proposed Rulemaking, a 60–90 day comment period, and a final rule — which published estimates put at 8 to 24 months out. The remaining five nominated peptides are scheduled for review before the end of February 2027. The vote record The committee reviewed each peptide against a specific proposed indication. Free base and acetate salt forms were voted separately; where forms split the same way, they are combined below. Peptide Indication FDA reviewed Vote (Y–N–Abstain) Outcome BPC-157 Ulcerative colitis 8–6–1 Recommended KPV Wound healing, inflammatory conditions 8–6–1 Recommended TB-500 (Thymosin Beta-4 fragment, LKKTETQ) Wound healing 8–6–1 Recommended MOTS-c Obesity, osteoporosis 7–5–2 Recommended Semax (heptapeptide) Cerebral ischemia, migraine, trigeminal neuralgia 8–5 Recommended Epitalon Insomnia 7–4 Recommended Emideltide (DSIP) Opioid withdrawal, chronic insomnia, narcolepsy 6–7–1 Not recommended Day one covered BPC-157, KPV, TB-500 and MOTS-c. Day two covered Emideltide, Semax and Epitalon. Note on tallies: day-one counts are consistent across FDA Law Blog, PharmExec and RAPS. Day-two abstention counts vary slightly between outlets; the yes–no figures above follow STAT News reporting from the meeting. The official record is the FDA meeting transcript and minutes. The unusual part: the panel overruled FDA's…
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.